NDRA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
ENDRA Life Sciences Inc (NDRA) is not a strong buy for a beginner, long-term investor with $50,000-$100,000 available for investment. The technical indicators are mixed, with bearish moving averages and no clear RSI signal. The company's financial performance is weak, with significant declines in net income and EPS. Additionally, there are no recent news catalysts, no significant insider or hedge fund activity, and no congress trading data to support a positive outlook. Given the lack of strong positive signals and the absence of Intellectia Proprietary Trading Signals, it is best to hold off on investing in NDRA at this time.
The MACD is positive and expanding, indicating slight bullish momentum. However, the RSI is neutral at 58.052, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 3.684, with resistance at 3.943 and support at 3.424.
The MACD is positively expanding, indicating slight bullish momentum. The stock has a 70% chance of gaining 4.51% in the next month based on historical candlestick patterns.
Bearish moving averages, weak financial performance with significant YoY declines in net income (-32.20%) and EPS (-99.37%), no recent news catalysts, and no significant insider or hedge fund activity.
In Q3 2025, the company's revenue remained at 0 with no YoY growth. Net income dropped by -32.20% YoY to -1,595,959, and EPS fell by -99.37% YoY to -2.1. Gross margin remained at 0 with no change.
No recent analyst ratings or price target changes available.
